DESTINY-PanTumor02

Representative image: Enhertu’s EU tumor-agnostic approval highlights how HER2 testing and precision oncology diagnostics could shape treatment access for advanced solid tumors.

Enhertu wins EU tumor-agnostic approval, but HER2 testing will decide its real impact

by Pallavi Madhiraju
June 30, 2026
0 Comments

The European approval takes Enhertu beyond organ-specific oncology, although its clinical reach will depend on reliable HER2 testing, reimbursement and safety management.

Representative image: Enhertu’s EU recommendation could expand HER2 targeted cancer treatment options for patients with previously treated metastatic solid tumors, highlighting the growing role of antibody drug conjugates and precision oncology in advanced cancer care.

Pharma & Biotech

Enhertu nears wider EU approval as HER2 testing moves deeper into solid tumor oncology

by Pallavi Madhiraju
May 23, 2026
0 Comments

Find out how Enhertu’s EU recommendation could reshape HER2 targeted treatment for metastatic solid tumors.